3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

Core Viewpoint - Growth investors are focused on stocks with above-average financial growth, which can lead to solid returns, but finding such stocks is challenging due to their inherent risks and volatility [1] Company Summary - ANI Pharmaceuticals (ANIP) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 2%, but projected EPS growth for this year is expected to be 22.2%, surpassing the industry average of 15.3% [4] - ANI's year-over-year cash flow growth is currently at 22.1%, significantly higher than the industry average of -4.4% [5] - The annualized cash flow growth rate for ANI over the past 3-5 years is 10.4%, compared to the industry average of 3.4% [6] - Current-year earnings estimates for ANI have been revised upward, with the Zacks Consensus Estimate increasing by 1.2% over the past month [7] - ANI has achieved a Growth Score of B and a Zacks Rank 1, indicating it is a potential outperformer and a solid choice for growth investors [9]